Eur J Cancer: Real clinical practice data of anti-PD-1 adjuvant treatment of melanoma!

Melanoma, usually referred to as malignant melanoma, is a highly malignant tumor derived from melanocytes, referred to as malignant melanoma, which occurs mostly in the skin, but also in mucous membranes and internal organs, accounting for about 3% of all tumors
.
Skin malignant melanoma accounts for the third place (about 6.

Although there are many clinical trials on the adjuvant therapy of melanoma, there are few data on the prognosis of melanoma patients who receive adjuvant therapy in the clinic
.
Starting in 2019, adjuvant melanoma patients will be registered on the DMTR ( a population-based registry for monitoring the quality and safety of melanoma diagnosis and treatment in the Netherlands )

This study aims to analyze the treatment mode, recurrence rate and adverse event rate of melanoma patients who actually receive adjuvant therapy in clinical practice through the patient data registered on the DMTR
.

Patients with melanoma who had received adjuvant therapy on DMTR were included
.
Use descriptive statistics to analyze patient characteristics and treatment characteristics

PFS of melanoma patients of different stages receiving adjuvant anti-PD-1 therapy

A total of 641 melanoma patients receiving adjuvant anti-PD-1 therapy were enrolled
.
After a median follow-up of 12.

Grade 3 and above toxic reactions during or after anti-PD-1 treatment

In summary, compared with clinical practice, in daily practice, anti-PD-1 adjuvant therapy after resection of stage III/IV melanoma showed a slightly higher toxicity rate and higher frequency of early discontinuation, but no progress Survival rates are similar

Original source:

de Meza Melissa M, Ismail Rawa K, Rauwerdink Daan et al.